Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H. Lundbeck ASFRA:LDBA +1.97%79 3-Year Book Growth Rate is 6.20% as of Jun. 2026, which is at its 10-year median of 6.20. GuruFocus rates FRA:LDBA with a GF Score™ of 79/100 and a GF Value™ of €5.20 (Fairly Valued). The stock has 5 warning signs investors should review. Among 912 Drug Manufacturers companies, H. Lundbeck AS ranks better than 56.25% on this metric.
During the past 12 months, H. Lundbeck AS's average Book Value per Share Growth Rate was 11.00% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 6.20% per year.
During the past 5 years, the average Book Value per Share Growth Rate was -24.70% per year.
During the past 10 years, the average Book Value per Share Growth Rate was -9.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of H. Lundbeck AS was 19.80% per year. The lowest was -37.20% per year. And the median was 6.20% per year.
H. Lundbeck AS (FRA:LDBA) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
H. Lundbeck AS 3-Year Book Growth Rate Related Terms
FRA:LDBA vs ZTS, UTHR, VTRS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's 3-Year Book Growth Rate falls into.
H. Lundbeck AS 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 6.20% mean?
H. Lundbeck AS (FRA:LDBA) has a 3-Year Book Growth Rate of 6.20% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for H. Lundbeck AS and its competitors. This is near median its historical median of 6.20. According to the industry distribution chart, H. Lundbeck AS ranks #399 out of 912 companies in the Drug Manufacturers industry, placing it in the top 43.7%.
Is H. Lundbeck AS's 3-Year Book Growth Rate too high?
H. Lundbeck AS's current 3-Year Book Growth Rate of 6.20% is near median its 10-year median of 6.20. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. H. Lundbeck AS's value of 6.20% is 34.8% above this industry median. Based on the distribution chart, H. Lundbeck AS ranks #399 out of 912 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, H. Lundbeck AS has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's 3-Year Book Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, H. Lundbeck AS ranks #399 out of 912 companies for 3-Year Book Growth Rate. This puts H. Lundbeck AS in the upper half of its industry. The industry median 3-Year Book Growth Rate is 4.60. H. Lundbeck AS's value of 6.20% is 34.8% above this benchmark. While the company's 10-year median is 6.20 vs. the industry median of 4.60, H. Lundbeck AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. H. Lundbeck AS's current 3-Year Book Growth Rate of 6.20% is 34.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for H. Lundbeck AS and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. H. Lundbeck AS's current 3-Year Book Growth Rate is 6.20%, which is near median its own 10-year median of 6.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Fairly Valued. The stock's GF Value™ is €5.20, compared to a current price of €5.70 — trading 9.6% above its estimated fair value. The current 3-Year Book Growth Rate is 6.20%, which is near median its 10-year median of 6.20 and 34.8% above the Drug Manufacturers industry median of 4.60. H. Lundbeck AS's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current 3-Year Book Growth Rate is 6.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be overvalued.
The current stock price of €5.70 is trading 9.6% above its estimated GF Value™ of €5.20.
GuruFocus considers H. Lundbeck AS to be Fairly Valued.
Key valuation signals for FRA:LDBA:
3-Year Book Growth Rate: 6.20% (near median its 10-year median of 6.20)
GF Value™: €5.20 vs. price of €5.70 (9.6% above fair value)
Industry Position: 34.8% above the Drug Manufacturers median (#399 of 912)
No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
79GF Score
Get the complete analysis for FRA:LDBA
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LDBA has been successfully added to your 
